Rocky Mountain High 株価情報 (OTC: RMHB)

最新ニュース Rocky Mountain High (OTC:RMHB) 株価情報

Rocky Mountain High Brands Inc is a brand management company. RMHB specializes in developing, manufacturing, marketing, and distributing high-quality, health-conscious, cannabidiol and hemp-infused products that span various categories including beverage, food, fitness, skincare, and more. It also markets a naturally high alkaline spring water as part of the company's brand portfolio.

ROCKY MTN HIGH BRAND INC by Rocky Mountain High Brands, Inc.

Rocky Mountain High Brands Inc

Goldman Sachs analyst Paul Choi maintains Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) with a Neutral and lowers the price target from $10 to $5.

News

Price Target

Analyst Ratings

PHAT

Goldman Sachs Maintains Neutral on Phathom Pharmaceuticals, Lowers Price Target to $5

Insider Trades

LWAY

Reported May, 1 2025: Lifeway Foods Form4 Filing Shows Ludmila Smolyansky Sold 20,518 Shares At An Average Price Of $23.77/Share

Stephens &amp; Co. analyst Terry McEvoy maintains First Mid Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FMBH#NASDAQ">FMBH</a>) with a Equal-Weight and lowers the price target from $43 to $41.

FMBH

Stephens & Co. Maintains Equal-Weight on First Mid Bancshares, Lowers Price Target to $41

Goldman Sachs analyst Brooke Roach maintains Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) with a Sell and raises the price target from $4 to $4.5.

Goldman Sachs Maintains Sell on Kohl's, Raises Price Target to $4.5

Goldman Sachs analyst Matthew Sykes maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Neutral and lowers the price target from $180 to $160.

ICLR

Goldman Sachs Maintains Neutral on Icon, Lowers Price Target to $160

Stephens &amp; Co. analyst Mason Carrico maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Overweight and lowers the price target from $140 to $115.

GKOS

Stephens & Co. Maintains Overweight on Glaukos, Lowers Price Target to $115

Goldman Sachs analyst Lizzie Dove maintains Hyatt Hotels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) with a Sell and raises the price target from $110 to $123.

Goldman Sachs Maintains Sell on Hyatt Hotels, Raises Price Target to $123

Goldman Sachs analyst Noah Poponak maintains Huntington Ingalls Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>) with a Buy and raises the price target from $236 to $265.

Goldman Sachs Maintains Buy on Huntington Ingalls Indus, Raises Price Target to $265

Shares of Polyrizon Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) surged 223% to 82 cents Friday afternoon, following a reversal in reverse stock split plans from Thursday.
What To Know: On Thursday morning, the company had announced a <a href="https://investor.polyrizon-biotech.com/pdfcontent/cik/1893645/id/d0555c49-8cb2-4fbd-9c9f-df32cb0bbfe3/file/ea0240173-6k_polyrizon.htm/to/000121390025038043_ea0240173-6k_polyrizon.pdf">1-for-10 reverse stock split</a>, intended to consolidate every ten shares into one, with trading on a post-split basis to begin May 5. The move originally aimed to bolster the company's per-share price, a common tactic to meet minimum listing requirements. 
However, late Thursday, Polyrizon <a href="https://investor.polyrizon-biotech.com/pdfcontent/cik/1893645/id/f7b4ddc3-bd8e-4976-9012-7c56b7348467/file/ea0240537-6k_polyrizon.htm/to/000121390025038530_ea0240537-6k_polyrizon.pdf">canceled the reverse split</a>, stating it would not proceed with the plan as previously disclosed. 
The change has triggered a flurry of speculative trading during Friday&#8217;s session, as the company provided no further explanation for the decision, leaving investors to interpret the implications. 
Friday&#8217;s volatility also highlights the sensitivity of small-cap stocks to corporate actions and the potential impact of sudden governance shifts.
Read Also: <a href="https://www.benzinga.com/25/05/45168400/apple-stock-falls-after-cook-warns-of-900m-tariff-impact">Apple Stock Falls After Cook Warns of $900M Tariff Impact</a>
<h2 class="wp-block-heading">How To Buy PLRZ Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Polyrizon&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, PLRZ has a 52-week high of $4.80 and a 52-week low of $0.25.

PLRZ

Polyrizon (PLRZ) Stock Skyrocketed Over 240% Today: What's Going On?

Stephens &amp; Co. analyst Terry McEvoy maintains Finward Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNWD#NASDAQ">FNWD</a>) with a Overweight and raises the price target from $32 to $34.

FNWD

Stephens & Co. Maintains Overweight on Finward Bancorp, Raises Price Target to $34

Goldman Sachs analyst Lizzie Dove maintains Hilton Grand Vacations (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGV#NYSE">HGV</a>) with a Sell and raises the price target from $30 to $34.

Goldman Sachs Maintains Sell on Hilton Grand Vacations, Raises Price Target to $34

Goldman Sachs analyst Neil Mehta maintains Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) with a Buy and lowers the price target from $27 to $24.

Goldman Sachs Maintains Buy on Halliburton, Lowers Price Target to $24

Stock Split

Reported May 1, 2025: Polyrizon Announced The Planned Reverse Share Split Of The Company's Ordinary Shares At The Ratio Of 1-For-10 That Was Previously Announced On May 1, 2025, Will Not Be Effectuated

Stephens &amp; Co. analyst Matt Olney maintains Cullen/Frost Bankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFR#NYSE">CFR</a>) with a Equal-Weight and raises the price target from $138 to $141.

Stephens & Co. Maintains Equal-Weight on Cullen/Frost Bankers, Raises Price Target to $141

Goldman Sachs analyst Kate McShane maintains Floor &amp; Decor Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FND#NYSE">FND</a>) with a Sell and lowers the price target from $81 to $70.

Goldman Sachs Maintains Sell on Floor & Decor Hldgs, Lowers Price Target to $70

Goldman Sachs analyst Will Nance maintains Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) with a Buy and lowers the price target from $65 to $57.

Goldman Sachs Maintains Buy on Block, Lowers Price Target to $57

Stephens &amp; Co. analyst Brett Huff maintains Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) with a Equal-Weight and lowers the price target from $255 to $221.

TEAM

Stephens & Co. Maintains Equal-Weight on Atlassian, Lowers Price Target to $221

Goldman Sachs analyst Paul Choi maintains Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) with a Neutral and lowers the price target from $12 to $8.

ARVN

Goldman Sachs Maintains Neutral on Arvinas, Lowers Price Target to $8

Goldman Sachs analyst Salveen Richter maintains Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) with a Neutral and lowers the price target from $12 to $9.

FOLD

Goldman Sachs Maintains Neutral on Amicus Therapeutics, Lowers Price Target to $9

In the high-stakes world of humanoid robotics, <a href="https://www.benzinga.com/topic/electric-vehicle">two EV titans</a> — Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and XPeng Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) — are competitors transforming this sector.
A CNBC <a href="https://www.cnbc.com/2025/04/29/how-to-play-a-5-trillion-market-for-humanoid-robots-by-2050.html">report </a>suggests that Morgan Stanley projects a $5 trillion global market for humanoid robots by 2050. Facts reveal that the race to dominate this new frontier is shaping up to be less &#8220;Fast &amp; Furious,&#8221; more &#8220;Iron Man&#8221; vs. &#8220;Iron Man.&#8221;
<h1 class="wp-block-heading">Optimus: Tesla&#8217;s FSD Tech-Powered Humanoid</h1>
Tesla&#8217;s Optimus is the better-known name, touted by Elon Musk as a full-stack humanoid built to tackle &#8220;mundane, repetitive, or dangerous tasks.&#8221; It stands at 5'8", powered by Tesla's Full Self-Driving (FSD) technology and integrates seamlessly with the company's vertically aligned AI and hardware ecosystem.
Optimus is expected to begin mass production this year, pending a little red tape from China. Rare earth export restrictions have thrown a wrench into Musk's plans, with the Chinese government scrutinizing the use of rare earth magnets amid geopolitical tensions. Musk insists the bots aren't weapons, but regulators still want assurances. That delay could slow down the thousands of Optimus units Tesla aims to build this year.
Read Also: <a href="https://www.benzinga.com/25/05/45134925/chinese-ev-companies-see-huge-april-growth-xpeng-surges-273-in-deliveries">Tesla&#8217;s Chinese Rivals See Huge April Growth, XPeng Surges 273% In Deliveries</a>
<h1 class="wp-block-heading">Iron: XPeng Blending Mobility &amp; Robotics In China</h1>
Enter XPeng's Iron, a <a href="https://carnewschina.com/2025/04/30/xpeng-showcases-humanoid-robot-iron-used-for-making-its-vehicls/">new contender</a> fresh off its Shanghai Auto Show flex. Iron isn't just hype — it's already working the production lines at XPeng, assembling EVs with precision. Standing at the same height as Optimus but packing more digital muscle — 3,000 TOPS of processing power, to be exact.
XPeng is literally putting Iron to work while Tesla navigates diplomatic speed bumps.
XPeng's edge lies in real-world deployment. Iron draws on the same AI that powers XPeng's autonomous vehicles, creating an end-to-end smart ecosystem that blends mobility and robotics. Its proprietary "Turing AI chip" and "Tianji AIOS" power everything from spatial awareness to voice interaction. With 60 joints and 200 degrees of freedom, Iron walks and works with a fluidity that&#8217;s caught the industry's eye.
<h1 class="wp-block-heading">62.7M Jobs &amp; A Trillion-Dollar Tech Transformation</h1>
Morgan Stanley calls Tesla a top potential winner due to its full-stack integration, but XPeng's Iron is proving it can punch above its weight. Both companies are chasing a future where humanoids take over not just factories but households and retail spaces. With projections of 62.7 million jobs replaced by robots by 2050 and a billion bots in use, this isn't science fiction — it's a trillion-dollar tech transformation.
So, who will build the next &#8220;Tony Stark&#8221; suit? Tesla may have the brand and brain trust, but XPeng is putting boots — or at least, metal feet — on the ground first.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45162888/uber-heats-up-robotaxi-battle-against-tesla-waymo-with-may-mobility-deal">Uber Heats Up Robotaxi Battle Against Tesla, Waymo With May Mobility Deal</a></li>
</ul>
Photos: Shutterstock

Comments

Rocky Mountain High

ニュース

最新ニュース Rocky Mountain High (OTC:RMHB) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル